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6/j.bSeveral studies have shown functional improvements, neuroprotective, and neuroregenerative effects after
mesenchymal stem cells transplantation to parkinsonian animal models. However, questions remain about
the safety, feasibility, and long-term efficacy of this approach. In this study, we investigated migration, thera-
peutic, tumorigenesis, and epileptogenic effects of human umbilical cord mesenchymal stromal cells
(HUMSCs) 1 year after transplantation into rotenone-induced hemiparkinsonian rats. Our data indicated
that DiI-labeled HUMSCs migrated in the lesioned hemisphere, from corpus striatum (CPu) to substantia
nigra. By integrating with host cells and differentiating into NSE, GFAP, Nestin, and tyrosine hydroxylase-
positive cells, HUMSCs prevented 48.4% dopamine neurons from degeneration and 56.9% dopamine termi-
nals from loss, both correlating with improvement of apomorphine-induced rotations. The CD50 and CD97
value of pentylenetetrazol and semiquantitative immunohistochemical analysis of proliferating cell nuclear
antigen (PCNA), b-catenin, C-myc, and NF-kB expression showed no significant difference between
HUMSCs transplanted and untransplanted groups, whereas the expressions of Bcl-2 and P53 in the grafted
CPu were upregulated by 281% and 200% compared to ungrafted CPu. The results of this long-term study
suggest that HUMSCs transplantation, 1 of the most potential treatments for Parkinson’s disease, is an effec-
tive and safe approach.
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bmt.2010.06.004pars compacta (SNc) and consequent loss of DA termi-
nals in the corpus striatum (CPu). The etiology and
pathogenesis of PD are not completely understood,
and the treatments of PD are limited. Although several
laboratory treatments have been shown to modify the
course of PD, there is still no treatment that could
halt or reverse the neurodegeneration in PD [1]. The
pathologic characteristics and treatment status make
PD a good target for cell therapy.
Several studies have shown the therapeutical bene-
fit of neural stem cells [2,3], embryonic stem cells [4,5],
bone marrow mesenchymal stem cells (BMSCs) [6,7],
induced pluripotent stem cells [8], and HUMSCs
[9-11] in parkinsonian animal models. However,
embryonic stem cells can form teratomas [12] and
are likely to elicit immune rejection if used for trans-
plantation [13], and the source of human neural stem
cells is limited. Moreover, the number of BMSCs,
which can be used for autologous transplantation for
the aging-associated PD [14], decreases steadily with
age [15]. Furthermore, induced pluripotent stem cells,1519
1520 Biol Blood Marrow Transplant 16:1519-1529, 2010N. Xiong et al.which could be derived from patients’ own cells, might
be associated with increased susceptibility to the de-
generative process of PD [16], as increased a-synuclein
expression was recently reported in Parkinson patient
fibroblasts [17]. Although early studies have indicated
the functional benefit from HUMSCs transplantation
[9-11], there is no data about the long-term therapeu-
tic effects, survivorship of HUMSCs, migration, fate
of differentiation, and long-term safety of HUMSCs
treatment.
Previous data demonstrated the potential antitu-
morigenic effects of human MSCs [18,19]. However,
embryonic stem cells and multipotent tissue-specific
stem cells still have the capacity to self-renew and to
differentiate into many different mature cell types,
and may share many signaling pathways with cancer
stem cells. Therefore, the long-term tumorigenesis
of HUMSCs must be carefully assessed before any
clinical application.
It is reported that neurologic complications such as
seizures attack might be among the consequences of
allogeneic BM transplantation [20]. Moreover, we
found a refractory epileptic patient who received um-
bilical cord blood transplantation 2 years ago and the
relationship between engraftments and seizures was
indistinct. It is rational for us to assess the epilepto-
genic effect in long-term stem cell therapy.
In this study, we transplanted 1,10-dioctadecyl-3,
3,30,30-tetramethylindocarbocyanine perchlorate (DiI)-
labeled HUMSCs to rotenone-induced hemiparkinso-
nian rats. After a period of 1 year, cellular migration in
the rat brain was detected by monitoring the red flour-
escence of DiI from the continuous frozen section of
brain tissue via a confocal microscopy. The efficacy
was assessed by the apomorphine-induced rotational
behaviors and tyrosine hydroxylase (TH) immuno-
reactivity in the CPu and SNc. The differentiation
fate of HUMSCs was examined by the immunohisto-
chemical staining of Nestin (neural stem cell marker),
Neuron-Specific Enolase (NSE, neuronal marker), glial
fibrillary acidic protein (GFAP, astrocyte marker) and
TH (dopaminergic marker). The safety was evaluated
by the p53, C-myc, H-RAS, b-catenin, Bcl-2, PCNA,
and NF-kB immunofluorescent staining, and the
CD50 and CD97 value of pentylenetetrazol (PTZ).METHODS
Preparation of HUMSCs
The experiments described here were approved by
the Ethical Committee of Tongji Medical College,
Huazhong University of Science and Technology,
China (HUST). With the permission of the parturient
(Gynecology and Obstetrics Department, Union
Hospital, HUST), umbilical cords were aseptically
collected during Cesarean sections, stored at 4C in0.01 M sterilized phosphate-buffered solution (PBS)
with heparin (20-30 U/mL) until further processing
[11]. To avoid endothelial cell contamination, umbili-
cal arteries and vein were removed and then the cords
were cut into small pieces (0.5–1 cm). Subsequently,
the cords were further cut into 1–2 mm3 fragments
and the explants were transferred into 6-well plates
containing the DMEM/F12 (Invitrogen, Carlsbad,
CA) along with 20% fetal bovine serum (Invitrogen)
and 10 ng/mL basic fibroblast growth factor (Pepro-
tech, Rocky Hill, NJ). Cultures were maintained at
37C in a humidified atmosphere containing 5%
CO2. The fragments were left undisturbed for 10-12
days to allow cells to migrate from the explants.
They were refed every 48-72 hours and passaged
(1:3) by trypsin (0.25%, Invitrogen) digestion until
cells reached 80%-90% confluency.HUMSCs Labeling
Cell labeling by DiI (Invitrogen) has been previously
described [21,22]. Briefly, HUMSCs were harvested by
treatment with 0.25% trypsin, washed with PBS, then
resuspended and incubated for 30 minutes at 37C
in darkness with growth media containing 10 mM DiI.
After washing with PBS 3 times (1000 rpm, 5
minutes), the DiI-labeled HUMSCs were used for
transplantation, or the detection of labeling efficiency
by flow cytometer or by confocal microscopy.Rotenone-Induced Hemiparkinsonian Rat
Model
The rotenone-induced slowly progressive hemi-
parkinsonian rodent model was chosen for this study
(23). Briefly, inbred adult female Sprague-Dawley
rats (220–260 g; from the Center of Experimental An-
imals, Tongji Medical College, HUST; 12-hour light/
dark cycles, 22 6 2C, 60% 6 5% humidity; standard
laboratory chow and water ad libitum) were anesthe-
tized with chloral hydrate (400 mg/kg in 0.9% NaCl,
intrasperitoneally [i.p.]) and fastened on a cotton bed
over a stereotaxic frame (RWD Life Science, Shenz-
hen, China). Rotenone dissolved in DMSO was in-
fused into the right ventral tegmental area (VTA,
AP: 5.0 mm; L: 1.0 mm; DV: 7.8 mm) at a flow rate
of 0.2 mL/minute. The needle was left in place for an
additional 5 minutes for complete diffusion of the
drug. Rotenone was infused into the right SNc (AP:
5.0 mm; L: 2.0 mm; DV: 8.0 mm) at a flow rate of
0.2 ml/minute, with a 5-minute needle retention. After
needle withdrawal, proper postoperative care was
given until the animals recovered completely. The
animals were given ibuprofen and penicillin in their
drinking water for 24 hours to alleviate potential post-
surgical discomfort and to prevent infection.
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Rats were divided randomly into 2 groups 4 weeks
after surgery: Saline group, 10 mL saline alone (without
donor cell administration) (n 5 12); and the HUMSC
group, 10 mL saline containing 1.0  106 DiI-labeled
HUMSCs (n 5 18). HUMSCs were transplanted
into the CPu of each rat (anterior 1.0 mm, lateral 3.0
mm, ventral 5.0 mm), based on positioning from the
bregma and skull surface. There was a 10-minute wait-
ing period before the needle was removed to allow the
cells to settle. No immunosuppressive medication was
given to the animals.
Apomorphine-Induced Rotations
Apomorphine (APO)-induced rotational behavior
was blindly tested every month for a total of 12 months
with coded animals. Rats were placed on a table (1 m 
1 m) with railing and allowed to acclimate to the envi-
ronment for 10 minutes, and then administered an in-
traperitoneal injection of APO (1.5 mg/kg) [23].
Subsequent rotational behavior was then recorded for
30 minutes. Following rotational testing, animals
were put back into their cages.
PTZ-Induced Seizures
The threshold for clonic convulsions was mea-
sured in all rats by intraperitoneal injection of PTZ
at doses ranging from 40 to 100 mg/kg. Following
the injection of PTZ, rats were placed separately into
transparent Plexiglas cages (80  80  40 cm) and
monitored for 30 minutes for the occurrence of clonic
seizures. Clonic seizure activity was defined as clonus
of the whole body lasting for more than 3 seconds,
with an accompanying loss of righting reflex. The
number of animals convulsing out of the total number
of rats tested was noted for each group. The convulsive
action of PTZ was evaluated as the CD50 (median
convulsive dose, that is, the dose of PTZ that produced
clonic seizures in 50% of the mice tested) and CD97
(the dose necessary to induce clonic seizures in 97%
of animals tested). To determine the CD50 and
CD97 values for control animals, 20 mg/kg to 80
mg/kg PTZ was used for testing (10 rats per group).
Subsequently, a dose-response curve was determined
from the percentage of rats convulsing according to
a log-probit method [24,25].
Histologic Examination of Grafted HUMSCs
One year after transplantation, rats were pro-
foundly anesthetized with chloral hydrate and the
brains were removed and postfixed for 12 hours in
4% paraformaldehyde in PBS at 4C. Next, the speci-
mens were equilibrated in PBS containing 15% su-
crose for 24 hours at 4C, then in 20% sucrose/PBS
for 24 hours at 4C, and finally, in 25% sucrose/PBS
for another 24 hours at 4C. Embedded in OCTcompound, brains were cut into serial 10-mm-thick sli-
ces by using a cryostat. Hematoxylin and eosin (HE)
stain was performed to detect tumor-like formations.
For differentiation and efficacy study, immunoflu-
orescent staining method was employed to assess Nes-
tin (mouse monoclonal antibody [mAb], Santa Cruz,
Santa Cruz, CA), NSE (mouse mAb, Abcam, Cam-
bridge, MA), GFAP (mouse mAb and rabbit poly-
clonal antibody, Santa Cruz), and TH (mouse mAb,
Millipore, Billerica, MA) expression in the CPu
(at 1.2 mm caudal to bregma), and TH (rabbit poly-
clonal antibody, Santa Cruz) expression in the SNc
(from 24.5 mm to 26.2 mm caudal to bregma), and
visualized by the fluorescein isothiocyanate (FITC)-
conjugated goat-antimouse IgG or FITC-conjugated
goat-antirabbit IgG (Proteintech, Chicago, IL). For
the safety study, the primary antibody NF-kB, p53,
C-myc, H-RAS, b-catenin, Bcl-2 (rabbit polyclonal
antibody, Santa Cruz), PCNA (mouse mAb, Cell
Signaling, Danvers, MA) and the corresponding sec-
ondary antibody FITC-conjugated goat-antimouse
IgG or FITC-conjugated goat-antirabbit IgG were
used. The slides from the anterior to posterior regions
of the left and right striata were densitometrically
observed and analyzed by employing the Image-Pro
plus 6.0 software package (Media Cybernetics, Inc.,
Bethesda, MD) [23]. A design-based, unbiased,
stereologic method and a morphometry/image analysis
system has been previously described for counting TH-
positive cells [23]. In each section, the region of interest
was outlined (SNc and VTA), and the TH-positive
cells/mm2 in that region were selected and semiauto-
matically counted.
Statistical Analysis
In tissue immunofluorescence staining, all tissue
manipulations were conducted in large batches to avoid
batch to batch variability. Following an experimenter-
blind fashion of data collection, analysis of variance
(ANOVA) was used to evaluate group differences. In
all statistical analyses, a P-value of\.05 was considered
statistically significant. All data were presented as mean
6 standard error.RESULTS
HUMSCsWere Highly Efficiently Labeled by DiI
After coculture with DiI for 30 minutes, 99.8% 6
0.1% of HUMSCs were labeled (Figure 1B-D). The
long spindle-shaped DiI-labeled cells were observed
under confocal microscopy (Figure 1A).
HUMSCs Migrated from the CPu to the SNc
The migration of grafted HUMSCs was visualized
by tracking the distribution of DiI fluorescence in
Figure 1. Labeling and migration of HUMSCs. (A) DiI-labeled HUMSCs were detected by confocal microscopy. (B) Scatter diagram of FSC/SSC gating.
(C) Unlabeled HUMSCs as a negative control. (D) 99.8% of HUMSCs were labeled by DiI. (E) Dorsal view of skull of transplanted rats. (I-K) The grafted
HUMSCs distribution in the cortex and CPu around the needle track. (F and L) HUMSCs distribution in the CPu 1 mm both rostrally and caudally to the
needle track. (H and M) HUMSCs distribution in the cortex and corpus callosum. (N and O) HUMSCs migration to the contralateral cerebral hemi-
sphere through the corpus callosum. (P) HUMSCs migration to the lesioned substantia nigra. (Q and R) HUMSCs migration to the lesioned VTA
and SNc. (Scale bars 5 50 mm.)
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tributed in the lesioned CPu (Figure 1F and I-L),
and a portion of the HUMSCs migrated to the
lesioned SNc and VTA (Figure 1P-R). HUMSCs
even migrated to the contralateral cerebral hemisphere
through the corpus callosum (Figure 1N-O).HUMSCs Significantly Reduced APO-Induced
Rotations in Parkinsonian Rats
After APO treatment, all the animals that received
unilateral rotenone infusion showed rotational behav-
ior. As expected, the rotational behavior of untreated
animals advanced gradually until the 12th month
(Figure 2A). Compared to the Saline group, the PD
model rats transplanted by the HUMSCs showed a sig-
nificant decrease in the number of rotations (Figure 2A).
Our data indicated, 12 months after transplantation,the HUMSC group decreased rotations by 67.48%
(Figure 2A).HUMSCs Preserved TH Immunoreactivity in
the CPu and SNc
The quantification study of TH-positive neurons
in the SNc demonstrated that the animals that ac-
cepted the transplantation had significantly more
TH-stained neurons in the SNc (Figure 2I: Saline
group; Figure 2J: HUMSC group; Figure 2C), which
was correlated with the TH immunoreactivity in the
CPu and behavioral recovery (Figure 2E: Saline group;
Figure 2F: HUMSC group; Figure 2B). Compared
with the contralateral CPu, the TH immunoreactivity
in the CPu of the Saline group was diminished by
92.08%, whereas it decreased by only 35.13% in the
CPu of the HUMSC group (Figure 2B and D-F).
Compared with the contralateral SNc, the number of
Biol Blood Marrow Transplant 16:1519-1529, 2010 1523Long-Term Efficacy and Safety of HUMSCTH-positive neurons of the lesioned SNc of the Saline
group was decreased by 79.68%, whereas it was re-
duced by only 31.28% in the lesioned SNc of HUMSC
group (Figure 2C, and H-J).HUMSCs Differentiated into Neuron-Like Cells
after Transplantation
Twelve months after implantation, human-
originated Nestin (Figure 3A-D), NSE (Figure 3E-H),
GFAP (Figure 3I-L), and TH (Figure 3M-P, mouse
mAb, Millipore) were detectable in the HUMSC group
(Figure 3A-P). Furthermore, these positive stained cells
were integrating with host cells (physical connection
with host cells; Figure 3). The immunofluorescence
staining of sections from the SNc showed that DiI-
labeled HUMSCs migrated to the SNc and differenti-
ated into TH-positive cells in the substantia nigra
(Figure 3Q-T, rabbit polyclonal antibody; Santa Cruz).Tumorigenesis Was Absent in Rats after Long-
Term HUMSCs Treatment
Immunohistostaining of Bcl-2, p53, PCNA, b-
catenin, and C-myc or HE staining (HE stain) was
used to examine any tumorigenesis of HUMSCs.
Our data showed that Bcl-2, an anti-apoptosis factor,
and the P53 tumor-suppressor protein were highly ex-
pressed in the DiI-labeled HUMSCs 12 months after
transplantation. Bcl-2 and P53 expressions in the
CPu of the HUMSC group (Bcl-2: Figure 4A-D;
P53: Figure 4I-L) were significantly different from
that in the lesioned CPu of the Saline group (Bcl-2:
Figure 4E-H; P53: Figure 4M-P): the expressions of
Bcl-2 and P53 in the grafted CPu were upregulated
by 281% and 200% compared to ungrafted CPu.
PCNA, b-catenin, C-myc, and NF-kB expressions
showed no difference between HUMSCs implanted
and unimplanted CPu (Figure 4Q-AN). Based on the
HE stain of the CPu (Figure 5B and C), especially
the regions besides the needle track, and the cortex
(Figure 5D and E), no tumor-like formations (duct-
like structures, irregular nests, malignant cell infiltra-
tion, or specific ultrastructural organization) were
observed, not even in proximity to the pin track.Epileptogenic Test Showed No Difference
between the Saline Group and the HUMSC
Group
The epileptogenic effect after long-term HUMSCs
transplantation was assessed by intraperitoneal injec-
tion of PTZ. CD50 and CD97 showed no significant
difference between the HUMSCs treated and un-
treated groups (Figure 5F-H). Unfortunately, 3 rats
from the Saline group and 2 rats from the HUMSC
group died 24 hours after PTZ treatment, and the
animal death was PTZ dose-related.DISCUSSION
In the present study, we showed that intra-CPu
transplantation of DiI-labeled HUMSCs 4 weeks after
rotenone-administration ameliorated APO-induced
rotations gradually in a period of 12 months, which indi-
cates long-term therapeutic effect of this approach.
HUMSCs migrated in the lesioned cerebral hemi-
sphere, from the CPu to the SNc, or even to the opposite
hemisphere through the corpus callosum. HUMSCs
survived for up to 12 months after transplantation, and
differentiated into Nestin-, NSE-, GFAP-, and TH-
positive cells in the CPu and TH-positive cells in the
SNc. No tumor-like structure was observed in the
implanted CPu, as confirmed by immunostaining of
Bcl-2, P53, PCNA,b-catenin, and C-myc. No immuno-
logic rejection or seizure attack was found without
immunosuppressant administration. CD50 and CD97
value of PTZ showed no significant difference between
HUMSCs implanted and unimplanted animals. Our
results indicate that HUMSC is an effective and safe
therapeutic alternative for PD.
Compared to the ‘‘gold standard’’ BMSCs,
HUMSCs showed a higher proliferative potential
than BMSCs and were capable of osteogenic, chondro-
genic, and adipogenic differentiation. However, there
are abundant similar characteristics between
HUMSCs and BMSCs that support the applicability
of HUMSCs for cell-based therapies because they
are all mesenchymal stem cells (MSCs) [26]. The
underlying mechanisms of the therapeutic efficacy of
MSCs could be summarized as follows: (1) neuropro-
tective effect: MSCs are capable of homing to the
impaired area and secreting neurotrophic factors that
support the survival of remanent neurons, induce
endogenous cell proliferation, and promote nerve fiber
regeneration [11,27-29]; (2) neuroregenerative effect:
in the cerebral nervous tissue niche, grafted MSCs
are able to differentiate into neurons and astrocytes
[11,30-32]; (3) immunomodulatory effect [33-35]:
MSCs suppress autoimmunity regardless of the
conditioning regimen, as a previous study showed that
MSC infusions lead to T cell anergy in experimental
autoimmune encephalomyelitis, with a decrease in
inflammatory infiltrates and demyelinization in treated
mice. Although evidence showed MSCs transdiffer-
entiated into neural cells, much remains to be done to
increase the rate of HUMSC differentiation into
a specified neuronal phenotype, such as DA neurons.
It was reported that 4 months after the transplanta-
tion of 1  105 in vitro HUMSCs-conversed TH-
positive cells (12.7%) into the CPu of parkinsonism
rats, these conversed cells migrated by 1.4 mm both
rostrally and caudally [10]. However, our data showed
that HUMSCs moved from the whole lesioned CPu to
the lesioned SNc, which was the result of the homing
capability of HUMSCs to the lesioned tissue. The
Figure 2. Effect of HUMSCs transplantation. (A) Rotational behavior of rats of Saline group versus HUMSC group. (B) TH immunoreactivity in the CPu
of Saline group versus HUMSC group. (C) Number of TH-positive neurons in the SNc of Saline group versus HUMSC group. (D-F) Immunofluorescence
staining of TH in the lesioned CPu of saline group (E), HUMSC group (F), and the contralateral CPu of both groups (D). (H-J) TH-positive cells in the
lesioned SNc of Saline group (I), HUMSC group (J), and the contralateral CPu of both groups (H), with nuclear staining by hoechst33258 (statistics con-
sisted of one-way ANOVA; )P\.05 compared to the contralateral side; #P\.05 compared to the Saline group; scale bars 5 50 mm).
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time points of the 2 studies and quantity of HUMSCs
implanted into the lesioned CPu, because ours were
10 times as much as that in the previous study. We
found that HUMSCs migrated to the opposite hemi-
sphere through the corpus callosum, consistent with
previous findings [6,10]. Furthermore, we found that
DiI-positive cells expressed TH in the lesioned SNc,
suggesting that HUMSCs migrated to the lesioned
SNc and differentiated into TH-positive cells. Unfor-
tunately, it is still unknown whether these HUMSCs-
derived TH-positive cells have the same functional
characteristics, electrophysiologic characteristics, and
synaptic connections as the DA neurons.In vitro studies have shown that MSCs can differen-
tiate into ecto- and endodermal derivates under specific
induced culture conditions [11,36-41]. In vivo studies
suggested that MSCs have the ability of differentiating
into multilineage cells of various tissues [42-46].
However, other researchers have proved that most
transplanted MSCs still retain their hematopoietic fate
[47], and MSCs underwent fusion rather than differenti-
ation in vitro and in vivo [48-50]. Our data showed that
under a long-term induction by the CPu niche,
HUMSCs differentiated into Nestin-, NSE-, GFAP-,
and TH-positive cells, suggesting that HUMSC is also
a good candidate for the treatment of other neurologic
disorders.
Figure 3. Differentiation fate of HUMSCs. DiI, HUMSCs tracker; hoechst33258, nuclear staining; Nestin, NSE, GFAP, and TH, all visualized by FITC-
conjunct goat-antimouse (or rabbit) IgG. (A-D) Coexpression of DiI and Nestin around the needle track. (E-H) Coexpression of DiI and NSE around the
needle track. (I-L) DiI-labeled HUMSCs and differentiation into GFAP-positive cells. (M-P) DiI-labeled HUMSCs and differentiation into TH-positive cells
in the microenvironment of CPu. (Q-T) DiI-labeled HUMSCs and migration to the lesioned SNc and differentiated into TH-positive cells (scale bars5
50 mm).
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Figure 4. Safety of long-term HUMSCs treatment. DiI for HUMSCs; p53, C-myc, b-catenin, Bcl-2, PCNA, and NF-kB all visualized by FITC-conjunct
goat-antirabbit or goat-antimouse IgG; Hoechst33258, nuclear staining. (A-D, I-L, Q-T, Y-AB, AG-AJ, and AO-AR) Bcl-2, P53, PCNA, b-catenin, C-myc,
and NF-kB expression in the HUMSCs-grafted CPu, respectively. (E-H, M-P, U-X, AC-AF, AK-AN, and AS-AV) Bcl-2, P53, PCNA, b-catenin, C-myc, and
NF-kB expression in the lesioned CPu of Saline group, respectively (scale bars 5 50 mm).
1526 Biol Blood Marrow Transplant 16:1519-1529, 2010N. Xiong et al.The potential safety hazards related to stem cell
transplantation is a predominant scruple in stem
cell therapy, although with distinct origins, stem cells
and tumor cells share many characteristics. Tumors
may often originate from the transformation of nor-
mal stem cells, and similar signaling pathways may
regulate self-renewal in stem cells and cancer cells
[51,52]. Therefore, HE staining and oncoprotein
immunohistostaining were employed in this study to
assess tumorigenesis of long-term HUMSCs trans-
plantation. Among the oncoproteins, Bcl-2, which
was upregulated by 281%, was shown to promote
cellular survival rather than proliferation [53]. Bcl-2
provided a distinct survival signal to the cells and may
contribute to neoplasia by allowing a clone to persist
until other oncogenes, such as c-myc, become activated
[53]. C-myc was reported to be a key factor that
involves tumorigenesis of stem cells [54]. P53, upregu-
lated by 200% in this study, was known as the most
important tumor suppressor, and its function is
lost in many types of cancers by mutation or by exces-
sive negative regulation, which initiates DNA repair,cell-cycle arrest, senescence, and apoptosis [55]. The
p53 and nuclear factor NF-kB pathways play crucial
roles in human cancer. Inactivation of p53 and hyperac-
tivation of NF-kB are common occurrences, and acti-
vation of p53 and inhibition of NF-kB both promote
apoptosis [56]. PCNA, a cell cycle marker protein, is
well known as a DNA sliding clamp for DNA polymer-
ase delta and as an essential component for eukaryotic
chromosomal DNA replication and repair [57]. Aber-
rant activation of the canonical WNT/b-catenin path-
way occurs in many cancers and contributes to their
growth, invasion, and survival, and dysregulated b-cat-
enin activity drives colon tumorigenesis [58]. Our data
showed that Bcl-2 and P53 expressions were signifi-
cantly different, whereas PCNA, b-catenin, C-myc,
and NF-kB expressions were no different between
HUMSCs implanted and unimplanted CPu. We spec-
ulated that overexpression of Bcl-2 is responsible for
the long-term survival of grafted HUMSCs, that p53
upregulation may play an important role in tumor su-
pression, and that the canonical expression of PCNA,
b-catenin, C-myc, and NF-kB in the HUMSC-
Figure 5. HE staining of brain tissue and PTZ-induced seizures. (A) Quantification of p53, C-myc, b-catenin, Bcl-2, PCNA, and NF-kB expression in the
HUMSCs implanted and unimplanted CPu. (B) HE stain of needle track in the lesioned CPu of HUMSC group. (C) HE stain of the contralateral CPu of
HUMSC group. (D) HE stain of the lesioned cortex of HUMSC group. (E) HE stain of the contralateral cortex of HUMSC group. (F) CD50 and CD97 of
PTZ-induced seizures in HUMSCs treated versus untreated groups. (G) Quantitative analysis of PTZ dosage in experimental animals. (H) Regression
analysis of PTZ-induced seizures in experimental animals ()P\.05 compared to Saline group; scale bars 5 50 mm).
Biol Blood Marrow Transplant 16:1519-1529, 2010 1527Long-Term Efficacy and Safety of HUMSCtransplanted CPu might minimize the possibility of
HUMSCs tumorigenesis. HE staining further con-
firmed this finding, as no tumor-like structure was
observed in the grafted CPu.
Another concern about stem cell treatment is the
epileptogenic effect of stem cells, which may result
from the wrong connection of the grafted cells to the
host cells, and induce abnormal cerebral neuronal
discharge and evoke seizures. None of the HUMSC
group rats showed any kind of seizure in the totalperiod of 12 months. To better assess the epileptogenic
effect of HUMSCs, PTZ, a chemical convulsant agent,
was used in this study. We found that the CD50 and
CD97 value of PTZ showed no significant difference
between HUMSC transplanted and untransplanted
rats, suggesting HUMSCs are unlikely induce seizures
in rodent models when used for transplantation.
We acknowledge the drawback of this study. The
long-term cell tracker DiI, with a highly lipophilic na-
ture of the carbocyanine dyes, may stain host cells
1528 Biol Blood Marrow Transplant 16:1519-1529, 2010N. Xiong et al.when the grafted cells disintegrate and release the dye.
Furthermore, the flourescence of DiI may quench
during this long period of time. Although the
human-specific primary antibodies were used as an in-
dependent method to confirm that the differentiated
cells were originally from human tissue, it was still un-
able to calculate recovery rate and differentiation rate
of the HUMSCs.
Given the observation that HUMSC transplanta-
tion is an effective and safety method for the treatment
of PD in rodent models, it still has a long way to go as
a clinical therapeutic alternative. Clinical trials indicate
that no long-term improvement of the neurologic con-
dition and survival has been consistently achieved after
the transplantation of human MSCs in stroke and other
neurodegenerative diseases [59]. Clinical trials are
quite different from the experimental animals, and
the pathogeneses of human diseases are much more
complicated than the lesion induced by experimental
agents. However, it is appreciated that BM stem cells
began their application in hematopoietic malignancies
only 8 years after hematopoietic stem cells showed their
treatment effectiveness in animal models. Further con-
firmation needs to be done in the effectiveness, safety,
and underlying mechanism of long-term HUMSCs
transplanted to nonhuman primates.ACKNOWLEDGMENTS
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